IMUX Stock News & Analysis | Latest Updates

Immunic to Participate in Investor and Scientific Conferences in September

(NASDAQ:IMUX) NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and...

September 4, 2025Investor

IMUX News

Immunic to Participate in Investor and Scientific Conferences in September

D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target

Immunic Announces Addl Data From Phase 2 CALLIPER Trial In Progressive MS, Supporting Recently Released Top-Line Results and Underlining Vidofludimus Calcium's Neuroprotective Potential

Immunic Completes Enrollment For Both Phase 3 ENSURE Trials Of Vidofludimus Calcium In Relapsing Multiple Sclerosis; Top-Line Data Expected End Of 2026

D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $10

Immunic Raises $65M in Public Offering, Could Gain $130M More From Warrant Exercises

Immunic Announces Proposed Public Offering; No Size Or Amount Disclosed

B. Riley Securities Reiterates Buy on Immunic, Lowers Price Target to $5

HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $10 Price Target

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Immunic Reports Data From Phase 2 CALLIPER Trial Of Nurr1 Activator, Vidofludimus Calcium, In Patients With Progressive Multiple Sclerosis

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% In Primary Progressive Multiple Sclerosis Patients From Phase 2 CALLIPER Trial

B. Riley Securities Reiterates Buy on Immunic, Maintains $6 Price Target

HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $10 Price Target

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Immunic, Announces Pricing Of $5.1M Registered Direct Offering At $0.90 Per Share Led by Aberdeen Investments

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

William Blair Initiates Coverage On Immunic with Outperform Rating

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Immunic Announced Presentation Of Data On Nuclear Receptor-Related 1 (Nurr1) Activator, Vidofludimus Aalcium (IMU-838), In Two Poster Presentations At The Americas Committee For Treatment And Research In Multiple Sclerosis Forum 2025

HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $10 Price Target

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Immunic Says Oral IMU-856 Demonstrated Dose-Dependent Increase Of GLP-1 In Celiac Disease Patients And Corresponding Effects in Preclinical Testing

Immunic Option Alert: Jun 17 $20 Calls Sweep (4) near the Ask: 1499 @ $0.6 vs 48 OI; Earnings 5/17 Before Open [est] Ref=$6.93